---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-025617"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T22:58:27.966342+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance prices $211M common stock offering at $9.15/share

## Summary
- Issues 23,014,000 shares at $9.15; gross proceeds ~$211M, net ~$197.1M.
- Net proceeds to support AMTAGVI commercial launch, NSCLC study IOV-LUN-202, melanoma trial TILVANCE-301.
- Underwriters include Jefferies, Barclays, Goldman Sachs; closing expected Feb 22, 2024.
- Executive officers and directors subject to 60-day lock-up on stock sales.

## SEC filing metadata
- accession: 0001104659-24-025617
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/0001104659-24-025617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/tm246746d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-025617
- JSON: https://secwatch.observer/filing/0001104659-24-025617.json
- Plain text: https://secwatch.observer/filing/0001104659-24-025617.txt

## Key facts
- Material Agreements
  IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC valued at approximately $197.1 million (effective 2024-02-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC
  - Value: approximately $197.1 million
  - Effective: 2024-02-20
  source text: On February 20, 2024, Iovance Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,014,000 shares of common stock (the “Shares”) (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/0001104659-24-025617-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.